Beam Therapeutics announces press release availability - BEAM News | RalliesBeam Therapeutics announces press release availability
B
BEAM• Press release availability and upcoming presentation
- Beam Therapeutics announced it will present updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency at ERS Congress 2026.
- A late-breaking oral presentation is scheduled for Sept. 8, 2026 in Barcelona; Beam plans a 7:00 a.m. ET investor webcast via beamtx.com.
- The update comes as Beam prepares to initiate a pivotal cohort for BEAM-302, its lead liver-targeting genetic disease program.
BWFG
•
